Search

Your search keyword '"Parikh, Sahil A"' showing total 504 results
Start Over Author "Parikh, Sahil A" Search Limiters Full Text
504 results on '"Parikh, Sahil A"'

1. Fully automated construction of three-dimensional finite element simulations from Optical Coherence Tomography

Author

Straughan, Ross, Kadry, Karim, Parikh, Sahil A., Edelman, Elazer R., and Nezami, Farhad R.

Subjects
Computer Science - Computational Engineering, Finance, and Science, Quantitative Biology - Tissues and Organs
Abstract

Despite recent advances in diagnosis and treatment, atherosclerotic coronary artery diseases remain a leading cause of death worldwide. Various imaging modalities and metrics can detect lesions and predict patients at risk; however, identifying unstable lesions is still difficult. Current techniques cannot fully capture the complex morphology-modulated mechanical responses that affect plaque stability, leading to catastrophic failure and mute the benefit of device and drug interventions. Finite Element (FE) simulations utilizing intravascular imaging OCT (Optical Coherence Tomography) are effective in defining physiological stress distributions. However, creating 3D FE simulations of coronary arteries from OCT images is challenging to fully automate given OCT frame sparsity, limited material contrast, and restricted penetration depth. To address such limitations, we developed an algorithmic approach to automatically produce 3D FE-ready digital twins from labeled OCT images. The 3D models are anatomically faithful and recapitulate mechanically relevant tissue lesion components, automatically producing morphologies structurally similar to manually constructed models whilst including more minute details. A mesh convergence study highlighted the ability to reach stress and strain convergence with average errors of just 5.9% and 1.6% respectively in comparison to FE models with approximately twice the number of elements in areas of refinement. Such an automated procedure will enable analysis of large clinical cohorts at a previously unattainable scale and opens the possibility for in-silico methods for patient specific diagnoses and treatment planning for coronary artery disease.

Published
2024
Full Text
View/download PDF

2. Percutaneous Mechanical Aspiration in Infective Endocarditis: Applications, Technical Considerations, and Future Directions.

Author

El Sabbagh, Abdallah, Yucel, Evin, Zlotnick, David, Moriarty, John, Younes, Stephanie, Hamid, Nadira, Akhtar, Yasir, Baddour, Larry, OGara, Patrick, Starck, Christoph, Bangalore, Sripal, Parikh, Sahil, Rosenfield, Kenneth, and Sethi, Sanjum

Subjects
cardiovascular implantable electronic device, endocarditis, injection drug use, outcomes, percutaneous mechanical aspiration, tricuspid valve
Abstract

In recent years, there has been a shift in the epidemiology of patients with infective endocarditis (IE). This has been characterized by an alarming increase in IE in patients who inject drugs, cardiac implantable electronic device-related IE, and those with comorbid conditions and high surgical risk. This unmet need has mandated a reevaluation of complex management strategies in these patients and introduction of unconventional approaches in treatment. Percutaneous mechanical aspiration has emerged as both a diagnostic and therapeutic option in selected patients with IE. In this review, the authors discuss the gaps in care of IE, rationale, device armamentarium, procedural, and technical considerations and applications of percutaneous mechanical aspiration in IE.

Published
2024

3. The Path to a Match for Interventional Cardiology Fellowship: A Major SCAI Initiative

Author

Drachman, Douglas E., Addo, Tayo, Applegate, Robert J., Bartel, Robert C., Bortnick, Anna E., Dea, Francesca M., Helmy, Tarek, Henry, Timothy D., Khalif, Adnan, Kirtane, Ajay J., Levy, Michael, Lim, Michael J., Mahmud, Ehtisham, Mihatov, Nino, Parikh, Sahil A., Porter, Laura, Prasad, Abhiram, Rao, Sunil V., Razzouk, Louai, Shah, Samit, Shroff, Adhir, Tamis-Holland, Jacqueline E., Velagapudi, Poonam, Welt, Fredrick G., and Abbott, J. Dawn

Published
2024
Full Text
View/download PDF

4. The shifting care and outcomes for patients with endangered limbs – Critical limb ischemia (SCOPE-CLI) registry overview of study design and rationale

Author

Scierka, Lindsey E, Mena-Hurtado, Carlos, Shishehbor, Mehdi H, Spertus, John A, Nagpal, Sameer, Babrowski, Trissa, Bunte, Matthew C, Politano, Amani, Humphries, Misty, Chung, Jayer, Kirksey, Lee, Alabi, Olamide, Soukas, Peter, Parikh, Sahil, Faizer, Rumi, Fitridge, Robert, Provance, Jeremy, Romain, Gaëlle, McMillan, Neil, Stone, Nancy, Scott, Kate, Fuss, Christine, Pacheco, Christina M, Gosch, Kensey, Harper-Brooks, Avis, Smolderen, Kim G, and Consortium, On behalf of the SCOPE-CLI Academic Research

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Research, Health Services, Good Health and Well Being, Peripheral Artery Disease, Critical Limb Ischemia, Study Design, Registries, Patient-Reported Outcomes, Health Disparities, SCOPE-CLI Academic Research Consortium, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

BackgroundCritical limb ischemia (CLI), the most severe form of peripheral artery disease, is associated with pain, poor wound healing, high rates of amputation, and mortality (>20% at 1 year). Little is known about the processes of care, patients' preferences, or outcomes, as seen from patients' perspectives. The SCOPE-CLI study was co-designed with patients to holistically document patient characteristics, treatment preferences, patterns of care, and patient-centered outcomes for CLI.MethodsThis 11-center prospective observational registry will enroll and interview 816 patients from multispecialty, interdisciplinary vascular centers in the United States and Australia. Patients will be followed up at 1, 2, 6, and 12 months regarding their psychosocial factors and health status. Hospitalizations, interventions, and outcomes will be captured for 12 months with vital status extending to 5 years. Pilot data were collected between January and July of 2021 from 3 centers.ResultsA total of 70 patients have been enrolled. The mean age was 68.4 ± 11.3 years, 31.4% were female, and 20.0% were African American.ConclusionsSCOPE-CLI is uniquely co-designed with patients who have CLI to capture the care experiences, treatment preferences, and health status outcomes of this vulnerable population and will provide much needed information to understand and address gaps in the quality of CLI care and outcomes.ClinicalTrials.gov identifier (NCT Number): NCT04710563 https://clinicaltrials.gov/ct2/show/NCT04710563.

Published
2022

7. Off-Label Use of Peripheral Paclitaxel Drug-Coated Balloons in Management of Recurrent Coronary In-Stent Restenosis

Author

Madhavan, Mahesh V., Hakemi, Emad, Neeranjun, Rishi, Rahim, Hussein M., Nouri, Shayan Nabavi, Flattery, Erin, Prasad, Megha, Collins, Michael B., Karmpaliotis, Dimitri, Ali, Ziad A., Parikh, Sahil A., Vahl, Torsten P., Patel, Amisha, Nazif, Tamim M., Fall, Khady N., Maehara, Akiko, Leon, Martin B., Kirtane, Ajay J., and Moses, Jeffrey W.

Published
2024
Full Text
View/download PDF

10. Consensus minimum core data elements adapted to peripheral vascular intervention in the drug-eluting era: Consensus report from the Registry Assessment of Peripheral Interventional Devices (RAPID) Pathways “LEAN” working group

Author

Black, James H., 3rd, Buckley, Donna, Velezis, Martha, Eldrup-Jorgensen, Jens, Serratore, Nina D., Gutierrez, Jorge A., Whatley, Eleni, Marmor, Rebecca A., Bertges, Daniel J., Tcheng, James E., Royce, Sara, Malone, Misti, Farb, Andrew, Secemsky, Eric A., Parikh, Sahil A., Smale, Joshua, Jaff, Michael R., White, Roseann, Wilgus, Rebecca W., and Krucoff, Mitchell W.

Published
2023
Full Text
View/download PDF

11. Association of Modified Body Mass Index With In-Hospital Outcomes After Intermediate or High-Risk Pulmonary Embolism

Author

Saleem, Danial, Madhavan, Mahesh V., Nigoghossian, Caroline Der, Driggin, Elissa, Nouri, Shayan N., Burton, John, Zilinyi, Robert, Snyder, Daniel J., Lumish, Heidi, Lavelle, Michael, Li, Jianhua, Rosenzweig, Erika B., Takeda, Koji, Kirtane, Ajay J., Fried, Justin, Brodie, Daniel, Agerstrand, Cara, Einstein, Andrew J., Maurer, Mathew, Parikh, Sahil A., Sethi, Sanjum S., and Finn, Matthew T.

Published
2023
Full Text
View/download PDF

15. Evaluation of an Infrapopliteal Drug-Eluting Resorbable Scaffold: Design Methodology for the LIFE-BTK Randomized Controlled Trial

Author

Varcoe, Ramon L., Parikh, Sahil A., DeRubertis, Brian G., Jones-McMeans, Jennifer M., Teraphongphom, Nutte Tarn, Wang, Jin, Kolluri, Raghu, Weinberg, Ido, Holden, Andrew H., Garcia-Garcia, Hector M., Kum, Steven W.C., Bonaca, Marc P., Bajakian, Danielle R., Garcia, Lawrence A., Krishnan, Prakash, Armstrong, Ehrin, Shishehbor, Mehdi H., Rundback, John, and Metzger, D. Chris

Published
2023
Full Text
View/download PDF

16. Platelet and Monocyte Activation After Transcatheter Aortic Valve Replacement (POTENT-TAVR): A Mechanistic Randomized Trial of Ticagrelor Versus Clopidogrel

Author

Zidar, David A., Al-Kindi, Sadeer, Longenecker, Chris T., Parikh, Sahil A., Gillombardo, Carl B., Funderburg, Nicholas T., Juchnowski, Steven, Huntington, Lauren, Jenkins, Trevor, Nmai, Christopher, Osnard, Michael, Shishebhor, Mehdi, Filby, Steven, Tatsuoka, Curtis, Lederman, Michael M., Blackstone, Eugene, Attizzani, Guilherme, and Simon, Daniel I.

Published
2023
Full Text
View/download PDF

17. 2023 ACC/AHA/SCAI Advanced Training Statement on Interventional Cardiology (Coronary, Peripheral Vascular, and Structural Heart Interventions): A Report of the ACC Competency Management Committee

Author

Bass, Theodore A., Abbott, J. Dawn, Mahmud, Ehtisham, Parikh, Sahil A., Aboulhosn, Jamil, Ashwath, Mahi L., Baranowski, Bryan, Bergersen, Lisa, Chaudry, Hannah I., Coylewright, Megan, Denktas, Ali E., Gupta, Kamal, Gutierrez, J. Antonio, Haft, Jonathan, Hawkins, Beau M., Herrmann, Howard C., Kapur, Navin K., Kilic, Sena, Lesser, John, Lin, C. Huie, Mendirichaga, Rodrigo, Nkomo, Vuyisile T., Park, Linda G., Phoubandith, Dawn R., Quader, Nishath, Rich, Michael W., Rosenfield, Kenneth, Sabri, Saher S., Shames, Murray L., Shernan, Stanton K., Skelding, Kimberly A., Tamis-Holland, Jacqueline, Thourani, Vinod H., Tremmel, Jennifer A., Uretsky, Seth, Wageman, Jessica, Welt, Frederick, Whisenant, Brian K., White, Christopher J., and Yong, Celina M.

Published
2023
Full Text
View/download PDF

24. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial

Author

Brilakis, Emmanouil S, Edson, Robert, Bhatt, Deepak L, Goldman, Steven, Holmes, David R, Rao, Sunil V, Shunk, Kendrick, Rangan, Bavana V, Mavromatis, Kreton, Ramanathan, Kodangudi, Bavry, Anthony A, Garcia, Santiago, Latif, Faisal, Armstrong, Ehrin, Jneid, Hani, Conner, Todd A, Wagner, Todd, Karacsonyi, Judit, Uyeda, Lauren, Ventura, Beverly, Alsleben, Aaron, Lu, Ying, Shih, Mei-Chiung, Banerjee, Subhash, Investigators, DIVA Trial, Ahmed, Bina, Ratliff, D Michelle, Ricciardi, Mark, Sheldon, Mark, Icenogle, Milton, Snider, Richard, Ardati, Amer, Nallamothu, Brahmajee, Duvernoy, Claire, Menees, Daniel S, Gurm, Hitinder, Thomas, Michael P, Grossman, Paul, Owen, Kristine, Topaz, On, Kumar, Gautam, Block, Peter, Zidar, David A, Bezerra, Hiram, Goldberg, Jonathan, Ortiz, Jose, Jozic, Joseph, Osman, Mohammed, Rosenthal, Noah, Parikh, Sahil A, Lassar, Tom A, Chan, Albert, Kumar, Arun, Aggarwal, Kul, Cyrus, Tillmann, Grodin, Jerrold, Hattler, Brack, Casserly, Ivan, Messenger, John, Kim, Michael, Rogers, R Kevin, Waldo, Stephen, Tsai, Thomas, Morris, Kenneth, Krucoff, Mitchell, Rao, Sunil, Povsic, Thomas J, Jones, William S, Bavry, Anthony, Choi, Calvin, Park, Ki, Liu, Jayson, Kar, Biswajit, Paniagua, David, Breall, Jeffrey, Bolad, Islam, Mukerji, Rita, Subbarao, Roopa, Abdel-Latif, Ahmed, Booth, David C, Ziada, Khaled M, Rajan, Lawrence, Hakeem, Abdul, Uretsky, Barry F, Agrawal, Mayank, Sachdeva, Rajesh, Ahmed, Zubair, McGee, Jesse, Shah, Rahman, Sharma, Alok, McFalls, Edward, Siddiqui, Rizwan, and Adabag, Selcuk

Subjects
Cardiovascular, Bioengineering, Clinical Research, Heart Disease, Clinical Trials and Supportive Activities, Patient Safety, Assistive Technology, Atherosclerosis, Heart Disease - Coronary Heart Disease, Aged, Double-Blind Method, Drug-Eluting Stents, Female, Graft Rejection, Humans, Male, Middle Aged, Percutaneous Coronary Intervention, Saphenous Vein, Self Expandable Metallic Stents, Thrombosis, Treatment Outcome, DIVA Trial Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundFew studies have examined the efficacy of drug-eluting stents (DES) for reducing aortocoronary saphenous vein bypass graft (SVG) failure compared with bare-metal stents (BMS) in patients undergoing stenting of de-novo SVG lesions. We assessed the risks and benefits of the use of DES versus BMS in de-novo SVG lesions.MethodsPatients were recruited to our double-blind, randomised controlled trial from 25 US Department of Veterans Affairs centres. Eligible participants were aged at least 18 years and had at least one significant de-novo SVG lesion (50-99% stenosis of a 2·25-4·5 mm diameter SVG) requiring percutaneous coronary intervention with intent to use embolic protection devices. Enrolled patients were randomly assigned, in a 1:1 ratio, by phone randomisation system to receive a DES or BMS. Randomisation was stratified by presence or absence of diabetes and number of target SVG lesions requiring percutaneous coronary intervention (one or two or more) within each participating site by use of an adaptive scheme intended to balance the two stent type groups on marginal totals for the stratification factors. Patients, referring physicians, study coordinators, and outcome assessors were masked to group allocation. The primary endpoint was the 12-month incidence of target vessel failure, defined as the composite of cardiac death, target vessel myocardial infarction, or target vessel revascularisation. The DIVA trial is registered with ClinicalTrials.gov, number NCT01121224.FindingsBetween Jan 1, 2012, and Dec 31, 2015, 599 patients were randomly assigned to the stent groups, and the data for 597 patients were used. The patients' mean age was 68·6 (SD 7·6) years, and 595 (>99%) patients were men. The two stent groups were similar for most baseline characteristics. At 12 months, the incidence of target vessel failure was 17% (51 of 292) in the DES group versus 19% (58 of 305) in the BMS group (adjusted hazard ratio 0·92, 95% CI 0·63-1·34, p=0·70). Between-group differences in the components of the primary endpoint, serious adverse events, or stent thrombosis were not significant. Enrolment was stopped before the revised target sample size of 762 patients was reached.InterpretationIn patients undergoing stenting of de-novo SVG lesions, no significant differences in outcomes between those receiving DES and BMS during 12 months of follow-up were found. The study results have important economic implications in countries with high DES prices such as the USA, because they suggest that the lower-cost BMS can be used in SVG lesions without compromising either safety or efficacy.FundingUS Department of Veterans Affairs Cooperative Studies Program.

Published
2018

25. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review

Author

Talasaz, Azita H., Sadeghipour, Parham, Aghakouchakzadeh, Maryam, Dreyfus, Isaac, Kakavand, Hessam, Ariannejad, Hamid, Gupta, Aakriti, Madhavan, Mahesh V., Van Tassell, Benjamin W., Jimenez, David, Monreal, Manuel, Vaduganathan, Muthiah, Fanikos, John, Dixon, Dave L., Piazza, Gregory, Parikh, Sahil A., Bhatt, Deepak L., Lip, Gregory Y.H., Stone, Gregg W., Krumholz, Harlan M., Libby, Peter, Goldhaber, Samuel Z., and Bikdeli, Behnood

Published
2021
Full Text
View/download PDF

27. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review

Author

Talasaz, Azita H., Sadeghipour, Parham, Kakavand, Hessam, Aghakouchakzadeh, Maryam, Kordzadeh-Kermani, Elaheh, Van Tassell, Benjamin W., Gheymati, Azin, Ariannejad, Hamid, Hosseini, Seyed Hossein, Jamalkhani, Sepehr, Sholzberg, Michelle, Monreal, Manuel, Jimenez, David, Piazza, Gregory, Parikh, Sahil A., Kirtane, Ajay J., Eikelboom, John W., Connors, Jean M., Hunt, Beverley J., Konstantinides, Stavros V., Cushman, Mary, Weitz, Jeffrey I., Stone, Gregg W., Krumholz, Harlan M., Lip, Gregory Y.H., Goldhaber, Samuel Z., and Bikdeli, Behnood

Published
2021
Full Text
View/download PDF

30. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Ringleb, Peter Arthur, Brown, Martin M., Dardik, Alan, Poredos, Pavel, Gray, William A., Nicolaides, Andrew N., Lal, Brajesh K., Mansilha, Armando, Antignani, Pier Luigi, de Borst, Gert J., Cambria, Richard P., Loftus, Ian M., Lavie, Carl J., Blinc, Ales, Lyden, Sean P., Matsumura, Jon S., Jezovnik, Mateja K., Bacharach, J. Michael, Meschia, James F., Clair, Daniel G., Zeebregts, Clark J., Lanza, Gaetano, Capoccia, Laura, Spinelli, Francesco, Liapis, Christos D., Jawien, Arkadiusz, Parikh, Sahil A., Svetlikov, Alexei, Menyhei, Gabor, Davies, Alun H., Musialek, Piotr, Roubin, Gary, Stilo, Francesco, Sultan, Sherif, Proczka, Robert M., Faggioli, Gianluca, Geroulakos, George, Fernandes e Fernandes, Jose, Ricco, Jean Baptiste, Saba, Luca, Secemsky, Eric A., Pini, Rodolfo, Myrcha, Piotr, Rundek, Tatjana, Martinelli, Ombretta, Kakkos, Stavros K., Sachar, Ravish, Goudot, Guillaume, Schlachetzki, Felix, Lavenson, George S., Ricci, Stefano, Topakian, Raffi, Millon, Antoine, Di Lazzaro, Vincenzo, Silvestrini, Mauro, Chaturvedi, Seemant, Eckstein, Hans Henning, Gloviczki, Peter, White, Christopher J., Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Ringleb, Peter Arthur, Brown, Martin M., Dardik, Alan, Poredos, Pavel, Gray, William A., Nicolaides, Andrew N., Lal, Brajesh K., Mansilha, Armando, Antignani, Pier Luigi, de Borst, Gert J., Cambria, Richard P., Loftus, Ian M., Lavie, Carl J., Blinc, Ales, Lyden, Sean P., Matsumura, Jon S., Jezovnik, Mateja K., Bacharach, J. Michael, Meschia, James F., Clair, Daniel G., Zeebregts, Clark J., Lanza, Gaetano, Capoccia, Laura, Spinelli, Francesco, Liapis, Christos D., Jawien, Arkadiusz, Parikh, Sahil A., Svetlikov, Alexei, Menyhei, Gabor, Davies, Alun H., Musialek, Piotr, Roubin, Gary, Stilo, Francesco, Sultan, Sherif, Proczka, Robert M., Faggioli, Gianluca, Geroulakos, George, Fernandes e Fernandes, Jose, Ricco, Jean Baptiste, Saba, Luca, Secemsky, Eric A., Pini, Rodolfo, Myrcha, Piotr, Rundek, Tatjana, Martinelli, Ombretta, Kakkos, Stavros K., Sachar, Ravish, Goudot, Guillaume, Schlachetzki, Felix, Lavenson, George S., Ricci, Stefano, Topakian, Raffi, Millon, Antoine, Di Lazzaro, Vincenzo, Silvestrini, Mauro, Chaturvedi, Seemant, Eckstein, Hans Henning, Gloviczki, Peter, and White, Christopher J.

Published
2024

31. Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials.

Author

Shah, Neil J., Della Pia, Alexandra, Wu, Tianmin, Williams, Aquino, Weber, Melinda, Sinclaire, Brittany, Gourna Paleoudis, Elli, Alaoui, Adil, Lev-Ari, Shaked, Adams, Shari, Kaufman, Jordan, Parikh, Sahil B., Tonti, Emily, Muller, Eric, Serzan, Michael, Cheruku, Divya, Lee, Albert, Sridhar, Aishwarya, Hee, Benjamin Perrin, and Ahn, Jaeil

Subjects
PATIENT safety, CLINICAL trials, SMOKING, TREATMENT effectiveness, IMMUNE system, RETROSPECTIVE studies, WHITE people, MULTIVARIATE analysis, IMMUNE checkpoint inhibitors, CELL lines, BLACK people, DRUG efficacy, AUTOIMMUNE diseases, STATISTICS, LUNG cancer, VIRUS diseases, TREATMENT failure, NIVOLUMAB, OVERALL survival, OBESITY
Abstract

Simple Summary: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used to treat a variety of cancers by helping a patient's own immune system to kill cancer cells. ICIs received their regulatory approval based on the results of large, randomized clinical trials. However, certain patient groups were excluded from these trials, so their outcomes are unknown. We performed a multicenter, retrospective study of real-world data in the United States in patients who had received at least one cycle of ICI treatment to evaluate the efficacy and safety of ICIs in patient groups underrepresented in clinical trials. Unique patient groups included age > 75 years, non-White race, positive smoking history, poor performance status, obesity, autoimmune diseases, chronic viral infections, multiple previous cancer therapies, or >three metastatic sites. Overall, ICIs were safe and efficacious in these patient groups. We noted that poor performance status and a history of multiple cancer therapies were associated with poor ICI efficacy, and Black patients, compared to White patients, experienced fewer immune-related adverse events. Regulatory approval of immune checkpoint inhibitors (ICIs) was based on results of large, randomized clinical trials, resulting in limited outcomes data in patient cohorts typically underrepresented in such trials. The objective of this study was to evaluate the efficacy and safety of ICIs in these unique patient cohorts. This is a multicenter, retrospective analysis of real-world data at six academic and community clinics in the United States from 1 January 2011 to 1 April 2018. Patients were included if they had received at least one cycle of ICI treatment. Unique patient cohorts included age > 75 years, non-White race, positive smoking history, ECOG performance status (PS) ≥ 2, BMI ≥ 30 kg/m2, autoimmune diseases (AIDs), chronic viral infections (CVI), extensive prior lines of therapy (LOTs), or >three metastatic sites. Immune-related adverse events (irAEs), overall survival (OS), and time to treatment failure were evaluated in the entire cohort and in NSCLC patients treated with PD-(L)1 monotherapy. Outcomes and their association with unique patient cohorts were compared on univariate analysis and multivariate analysis to those without a particular characteristic in the entire NSCLC PD-(L)1 monotherapy cohorts. In total, 1453 patients were included: 56.5%—smokers, 30.4%—non-White, 22.8%—elderly, 20.8%—ECOG PS ≥ 2, 15.7%—history of AIDs, and 4.7%—history of CVI. The common ICIs were nivolumab (37.1%) and pembrolizumab (22.2%). Black patients, compared to White patients, experienced fewer irAEs (OR 0.54, p < 0.001). An ECOG PS of ≥2 (HR = 2.01, p < 0.001) and an increased number of previous LOTs were associated with poor OS (the median OS of 26.2 vs. 16.2 vs. 9.6 months for one vs. two vs. three prior LOTs, p < 0.001). The above results were confirmed in anti-PD-(L)1 monotherapy non-small cell lung cancer patients (n = 384). Overall, ICIs were safe and efficacious in these typically underrepresented patient cohorts. We noted ECOG PS ≥ 2 and an increased prior LOTs were associated with poor ICI efficacy, and Black patients, compared to White patients, experienced fewer irAEs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Intravascular ultrasound use in peripheral arterial and deep venous interventions: Multidisciplinary expert opinion from SCAI/AVF/AVLS/SIR/SVM/SVS

Author

Secemsky, Eric A., primary, Aronow, Herbert D., additional, Kwolek, Christopher J., additional, Meissner, Mark, additional, Muck, Patrick E., additional, Parikh, Sahil A., additional, Winokur, Ronald S., additional, George, Jon C., additional, Salazar, Gloria, additional, Murphy, Erin H., additional, Costantino, Mary M., additional, Zhou, Wei, additional, Li, Jun, additional, Lookstein, Robert, additional, and Desai, Kush R., additional

Published
2024
Full Text
View/download PDF

33. Modern Radiation Therapy and Cardiac Outcomes in Breast Cancer

Author

Boero, Isabel J, Paravati, Anthony J, Triplett, Daniel P, Hwang, Lindsay, Matsuno, Rayna K, Gillespie, Erin F, Yashar, Catheryn M, Moiseenko, Vitali, Einck, John P, Mell, Loren K, Parikh, Sahil A, and Murphy, James D

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Heart Disease - Coronary Heart Disease, Heart Disease, Prevention, Aging, Breast Cancer, Cardiovascular, Cancer, 2.4 Surveillance and distribution, Aetiology, Good Health and Well Being, Aged, Aged, 80 and over, Arrhythmias, Cardiac, Confidence Intervals, Female, Heart, Heart Diseases, Humans, Medicare, Myocardial Ischemia, Percutaneous Coronary Intervention, SEER Program, Unilateral Breast Neoplasms, United States, Other Physical Sciences, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Theoretical and computational chemistry, Medical and biological physics
Abstract

PurposeAdjuvant radiation therapy, which has proven benefit against breast cancer, has historically been associated with an increased incidence of ischemic heart disease. Modern techniques have reduced this risk, but a detailed evaluation has not recently been conducted. The present study evaluated the effect of current radiation practices on ischemia-related cardiac events and procedures in a population-based study of older women with nonmetastatic breast cancer.Methods and materialsA total of 29,102 patients diagnosed from 2000 to 2009 were identified from the Surveillance, Epidemiology, and End Results-Medicare database. Medicare claims were used to identify the radiation therapy and cardiac outcomes. Competing risk models were used to assess the effect of radiation on these outcomes.ResultsPatients with left-sided breast cancer had a small increase in their risk of percutaneous coronary intervention (PCI) after radiation therapy-the 10-year cumulative incidence for these patients was 5.5% (95% confidence interval [CI] 4.9%-6.2%) and 4.5% (95% CI 4.0%-5.0%) for right-sided patients. This risk was limited to women with previous cardiac disease. For patients who underwent PCI, those with left-sided breast cancer had a significantly increased risk of cardiac mortality with a subdistribution hazard ratio of 2.02 (95% CI 1.23-3.34). No other outcome, including cardiac mortality for the entire cohort, showed a significant relationship with tumor laterality.ConclusionsFor women with a history of cardiac disease, those with left-sided breast cancer who underwent radiation therapy had increased rates of PCI and a survival decrement if treated with PCI. The results of the present study could help cardiologists and radiation oncologists better stratify patients who need more aggressive cardioprotective techniques.

Published
2016

34. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19

Author

Gupta, Aakriti, Madhavan, Mahesh V., Poterucha, Timothy J., DeFilippis, Ersilia M., Hennessey, Jessica A., Redfors, Bjorn, Eckhardt, Christina, Bikdeli, Behnood, Platt, Jonathan, Nalbandian, Ani, Elias, Pierre, Cummings, Matthew J., Nouri, Shayan N., Lawlor, Matthew, Ranard, Lauren S., Li, Jianhua, Boyle, Claudia, Givens, Raymond, Brodie, Daniel, Krumholz, Harlan M., Stone, Gregg W., Sethi, Sanjum S., Burkhoff, Daniel, Uriel, Nir, Schwartz, Allan, Leon, Martin B., Kirtane, Ajay J., Wan, Elaine Y., and Parikh, Sahil A.

Published
2021
Full Text
View/download PDF

35. Extrapulmonary manifestations of COVID-19

Author

Gupta, Aakriti, Madhavan, Mahesh V., Sehgal, Kartik, Nair, Nandini, Mahajan, Shiwani, Sehrawat, Tejasav S., Bikdeli, Behnood, Ahluwalia, Neha, Ausiello, John C., Wan, Elaine Y., Freedberg, Daniel E., Kirtane, Ajay J., Parikh, Sahil A., Maurer, Mathew S., Nordvig, Anna S., Accili, Domenico, Bathon, Joan M., Mohan, Sumit, Bauer, Kenneth A., Leon, Martin B., Krumholz, Harlan M., Uriel, Nir, Mehra, Mandeep R., Elkind, Mitchell S. V., Stone, Gregg W., Schwartz, Allan, Ho, David D., Bilezikian, John P., and Landry, Donald W.

Published
2020
Full Text
View/download PDF

37. Vascular Teams in Peripheral Vascular Disease

Author

Kolte, Dhaval, Parikh, Sahil A., Piazza, Gregory, Shishehbor, Mehdi H., Beckman, Joshua A., White, Christopher J., Jaff, Michael R., Iribarne, Alexander, Nguyen, Tom C., Froehlich, James B., Rosenfield, Kenneth, and Aronow, Herbert D.

Published
2019
Full Text
View/download PDF

39. ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine

Author

Bailey, Steven R., Beckman, Joshua A., Dao, Timothy D., Misra, Sanjay, Sobieszczyk, Piotr S., White, Christopher J., Wann, L. Samuel, Dao, Timothy, Aronow, Herbert D., Fazel, Reza, Gornik, Heather L., Gray, Bruce H., Halperin, Jonathan L., Hirsch, Alan T., Jaff, Michael R., Krishnamurthy, Venkataramu, Parikh, Sahil A., Reed, Amy B., Shamoun, Fadi, Shugart, Rita E., and Yucel, E. Kent

Published
2019
Full Text
View/download PDF

40. Association Between Diagnosis-to-Limb Revascularization Time and Clinical Outcomes in Outpatients With Chronic Limb-Threatening Ischemia: Insights From the CLIPPER Cohort.

Author

Fanaroff, Alexander C., Dayoub, Elias J., Lin Yang, Schultz, Kaitlyn, Ramadan, Omar I., Wang, Grace J., Damrauer, Scott M., Genovese, Elizabeth A., Secemsky, Eric A., Parikh, Sahil A., Nathan, Ashwin S., Kohi, Maureen P., Weinberg, Mitchell D., Jaff, Michael R., Groeneveld, Peter W., and Giri, Jay S.

Published
2024
Full Text
View/download PDF

43. Peripheral Vascular Intervention Training—Gaps and Solutions

Author

Ijioma, Nkechinyere N., primary, Box, Lyndon C., additional, Feldman, Dmitriy N., additional, Giri, Jay S., additional, Khalil, Mazen K., additional, Klein, Andrew J., additional, Latif, Faisal, additional, Li, Jun, additional, Parikh, Sahil A., additional, Brezzell, Mark, additional, Brockman, Ben, additional, Canorea-Vega, Fely, additional, Doherty, Shannon, additional, Donnelly, Gina, additional, Fuller, David, additional, Garman, Alissa, additional, Ghizoni, Philip, additional, Hampson, Kalei, additional, Keeler, Keeli N., additional, Lonn, Linda, additional, Martinelli, Mike, additional, McGlone, Chris, additional, Ngo, Mahn-Dan, additional, Tu, Thomas, additional, Voll, Erica, additional, and Wimberger, Jude, additional

Published
2023
Full Text
View/download PDF

44. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Paraskevas, Kosmas I., primary, Mikhailidis, Dimitri P., additional, Ringleb, Peter Arthur, additional, Brown, Martin M., additional, Dardik, Alan, additional, Poredos, Pavel, additional, Gray, William A., additional, Nicolaides, Andrew N., additional, Lal, Brajesh K., additional, Mansilha, Armando, additional, Antignani, Pier Luigi, additional, de Borst, Gert J., additional, Cambria, Richard P., additional, Loftus, Ian M., additional, Lavie, Carl J., additional, Blinc, Ales, additional, Lyden, Sean P., additional, Matsumura, Jon S., additional, Jezovnik, Mateja K., additional, Bacharach, J. Michael, additional, Meschia, James F., additional, Clair, Daniel G., additional, Zeebregts, Clark J., additional, Lanza, Gaetano, additional, Capoccia, Laura, additional, Spinelli, Francesco, additional, Liapis, Christos D., additional, Jawien, Arkadiusz, additional, Parikh, Sahil A., additional, Svetlikov, Alexei, additional, Menyhei, Gabor, additional, Davies, Alun H., additional, Musialek, Piotr, additional, Roubin, Gary, additional, Stilo, Francesco, additional, Sultan, Sherif, additional, Proczka, Robert M., additional, Faggioli, Gianluca, additional, Geroulakos, George, additional, Fernandes e Fernandes, Jose, additional, Ricco, Jean-Baptiste, additional, Saba, Luca, additional, Secemsky, Eric A., additional, Pini, Rodolfo, additional, Myrcha, Piotr, additional, Rundek, Tatjana, additional, Martinelli, Ombretta, additional, Kakkos, Stavros K., additional, Sachar, Ravish, additional, Goudot, Guillaume, additional, Schlachetzki, Felix, additional, Lavenson, George S., additional, Ricci, Stefano, additional, Topakian, Raffi, additional, Millon, Antoine, additional, Di Lazzaro, Vincenzo, additional, Silvestrini, Mauro, additional, Chaturvedi, Seemant, additional, Eckstein, Hans-Henning, additional, Gloviczki, Peter, additional, and White, Christopher J., additional

Published
2023
Full Text
View/download PDF

45. Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis

Author

Paraskevas, Kosmas I., primary, Brown, Martin M., additional, Lal, Brajesh K., additional, Myrcha, Piotr, additional, Lyden, Sean P., additional, Schneider, Peter A., additional, Poredos, Pavel, additional, Mikhailidis, Dimitri P., additional, Secemsky, Eric A., additional, Musialek, Piotr, additional, Mansilha, Armando, additional, Parikh, Sahil A., additional, Silvestrini, Mauro, additional, Lavie, Carl J., additional, Dardik, Alan, additional, Blecha, Matthew, additional, Liapis, Christos D., additional, Zeebregts, Clark J., additional, Nederkoorn, Paul J., additional, Poredos, Peter, additional, Gurevich, Victor, additional, Jawien, Arkadiusz, additional, Lanza, Gaetano, additional, Gray, William A., additional, Gupta, Ajay, additional, Svetlikov, Alexei V., additional, Fernandes e Fernandes, Jose, additional, Nicolaides, Andrew N., additional, White, Christopher J., additional, Meschia, James F., additional, Cronenwett, Jack L., additional, Schermerhorn, Marc L., additional, and AbuRahma, Ali F., additional

Published
2023
Full Text
View/download PDF

47. TCT-566 Tyrosine Polycarbonate Bioresorbable Scaffold for Below-the-Knee Application: Pilot Study of Biocompatibility in Small-Caliber Porcine Peripheral Arteries

Author

Kachel, Mateusz, primary, Melo, Pedro, additional, Cheng, Yanping, additional, Conditt, Gerard, additional, Gram, Danielle, additional, Anderson, Jeffrey, additional, Rousselle, Serge, additional, Granada, Juan, additional, Parikh, Sahil, additional, and Kaluza, Grzegorz, additional

Published
2023
Full Text
View/download PDF

49. TCT-616 IVUS as an Adjunct to Digital Subtraction Angiography in the Treatment of Peripheral Arterial Disease

Author

Saleem, Danial, primary, Dreyfus, Isaac, additional, Snyder, Daniel, additional, Zilinyi, Robert, additional, Min, Sugi, additional, Fall, Khady, additional, Maehara, Akiko, additional, Mintz, Gary, additional, Sethi, Sanjum, additional, Pucillo, Anthony, additional, Kirtane, Ajay, additional, Finn, Matthew, additional, and Parikh, Sahil, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results